Alzamend Neuro (ALZN) Net Income towards Common Stockholders (2020 - 2026)

Alzamend Neuro has disclosed Net Income towards Common Stockholders across 7 years of filings, most recently posting -$2.9 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 74.75% year-over-year to -$2.9 million; the TTM figure through Apr 2026 stood at -$8.8 million (down 71.84% YoY), while the FY2026 annual figure was -$8.8 million, down 71.84% from the prior year.
• Net Income towards Common Stockholders came in at -$2.9 million for Q2 2026 at Alzamend Neuro, down from -$2.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$851529.0 in Q2 2024 to a low of -$5.4 million in Q1 2023.
• Average Net Income towards Common Stockholders over 5 years is -$2.5 million, with a median of -$2.7 million recorded in 2024.
• Year-over-year, Net Income towards Common Stockholders plunged 208.83% in 2022 and soared 74.24% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$3.1 million in 2022, then rose by 6.56% to -$2.9 million in 2023, then jumped by 51.3% to -$1.4 million in 2024, then grew by 29.29% to -$1.0 million in 2025, then sank by 186.78% to -$2.9 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$2.9 million in Q2 2026, -$2.2 million in Q1 2026, and -$1.0 million in Q4 2025.